A Phase 1b, Open Label Study to Evaluate the Safety and Efficacy of TRU 016 in Combination With Rituximab, in Combination With Obinutuzumab, in Combination With Rituximab and Idelalisib, or in Combination With Ibrutinib in Patients With Chronic Lymphocytic Leukemia

Trial Profile

A Phase 1b, Open Label Study to Evaluate the Safety and Efficacy of TRU 016 in Combination With Rituximab, in Combination With Obinutuzumab, in Combination With Rituximab and Idelalisib, or in Combination With Ibrutinib in Patients With Chronic Lymphocytic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Otlertuzumab (Primary) ; Ibrutinib; Idelalisib; Obinutuzumab; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Aptevo Therapeutics; Emergent Product Development Seattle
  • Most Recent Events

    • 28 Nov 2017 According to an Aptevo Therapeutics media release, the company is planning to discontinue enrollment in the ongoing cohorts evaluating otlertuzumab in CLL.
    • 09 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2018.
    • 09 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top